Overview of Altargo

Property	Description
Active Ingredient	Retapamulin
Form	Ointment (1% w/w)
Pharmacological Class	Pleuromutilin Antibacterial
General Purpose	Treating superficial skin infections (e.g., impetigo)
Origin	Semisynthetic derivative (of pleuromutilin)
Status	Prescription-only (Rx)

Altargo is a prescription-only topical antibiotic designed for direct application to the skin to combat bacterial growth associated with superficial skin infections. Its active ingredient is Retapamulin, which is classified within the pleuromutilin antibacterial pharmacological class.

Retapamulin is a semisynthetic pleuromutilin derivative that represents a unique therapeutic option; the compound is derived from pleuromutilin, a substance obtained through fungal fermentation. Retapamulin is recognized as the first pleuromutilin antibiotic approved for human use.

The Altargo brand is formulated exclusively as a 1% w/w ointment, its dosage form, intended solely for cutaneous use. The preparation is primarily composed of Retapamulin dispersed in a white soft paraffin base. This specific ointment preparation ensures the antibacterial medicine remains concentrated on the localized area of the skin, maximizing its impact against targeted bacteria.

The overall purpose of using Altargo is to contain and resolve infections by targeted action against susceptible bacteria, such as those causing uncomplicated bacterial skin and skin structure infections (SSSIs). Its activity is clinically recognized for its distinct mode of action as a protein synthesis inhibitor. This unique mechanism helps limit the possibility of cross-resistance with older antibiotic classes.

What side effects are possible with Altargo?

Possible side effects and safety information

The safety profile for Altargo (retapamulin) ointment is established through clinical studies, with adverse reactions generally related to its topical application. Official regulatory documents classify these effects, grouping them by frequency and the body system affected.

Frequency Classification and System-Organ Effects

The most frequent adverse reaction documented is application site irritation, classified as common (affecting 1 to 10 users in 100). Reactions classified as uncommon (affecting 1 to 10 users in 1,000) include other administration site conditions like pain, pruritus (itching), and erythema (redness), as well as contact dermatitis.

Non-local effects reported in clinical trials include headache, diarrhea, and nausea. These effects are grouped into system-organ classes such as General disorders and administration site conditions, Skin and subcutaneous tissue disorders, and Gastrointestinal Disorders.

Serious Reactions and Safety Constraints

Serious adverse reactions reported post-marketing, with a frequency classified as not known, include hypersensitivity reactions, specifically angioedema (swelling). The ointment is strictly for cutaneous use and is not intended for use in the eyes, nose, or vagina.

Prolonged use of the antibiotic carries the regulatory-documented potential for superinfection caused by the overgrowth of non-susceptible microorganisms, including fungi. The excipient Butylated Hydroxytoluene (BHT), present in the ointment, is noted to potentially cause local skin reactions.

Population-Specific Notes

Safety and efficacy have not been established for use in pediatric patients younger than nine months of age. Specific caution is advised for children between 9 months and 2 years of age who are also receiving strong inhibitors of the CYP3A4 enzyme, as this may lead to increased systemic exposure.

Overdose and Emergency Response

Altargo Overdose and When to Seek Help: Official Regulatory Information

The official regulatory information for Altargo overdose addresses potential exposure scenarios and the mandatory response actions, rather than listing specific toxicological syndromes.

Documented Overdose Scope

Overdosage has not been reported in clinical studies; therefore, specific clinical manifestations are not formally described in the prescribing information.
Potential overdose exposure is described for both excessive topical application and accidental ingestion of the ointment.
No population-specific overdose considerations for severity or management are detailed in the official regulatory sections for populations such as pediatrics or patients with organ impairment.

Required Emergency Response

Any signs or symptoms resulting from a suspected overdose event should be treated symptomatically consistent with good clinical practice.
It is confirmed that no specific antidote is known for overdose of the Retapamulin ointment.

When Immediate Medical Help is Required

Emergency medical services must be contacted immediately if the individual exhibits severe symptoms such as trouble breathing, collapse, seizure, or inability to be awakened following exposure.
The procedural guidance emphasizes immediate help-seeking for any life-threatening signs, irrespective of the overdose mechanism.

Connection to the Overall Overdose Profile Regulatory documents define the overdose profile primarily by the absence of reported clinical data, constraining the information to potential exposure routes and procedural responses. This results in a profile that mandates a supportive approach where all clinical manifestations are managed symptomatically, alongside the critical instruction to contact emergency services for any severe, systemic signs.

Therapeutic Uses of Altargo

What Altargo Treats: Main Uses and Benefits

Altargo is an antibacterial treatment that is commonly used to help manage symptoms related to inflammatory or irritative states caused by susceptible bacteria on the skin surface. The medication is considered relevant for the topical treatment of specific uncomplicated bacterial skin and skin structure infections (SSSIs) in patients aged nine months and older.

It is primarily used for managing primary impetigo and for addressing secondary bacterial infections complicating conditions such as small traumatic lesions (minor cuts or abrasions) and chronic dermatoses (like infected eczema). It helps address symptom clusters that may become intense or disruptive, such as heightened redness, swelling, and increased fluid discharge.

“This topical agent is commonly used to help manage the localized symptoms resulting from superficial bacterial presence.”

This provides support that helps ease the overall symptom burden during the acute infectious phase, and may assist in supporting the affected area during the healing process. It is applied when supportive symptom management is appropriate for infections caused by Staphylococcus aureus or Streptococcus pyogenes that are superficial and localized.

Quick Fact: Relief for Inflammatory Symptoms The product is applied in clinical settings that involve acute or unstable symptom patterns on the skin, and is commonly used to help manage the visible signs of bacterial infection, including oozing, crusting, and localized inflammation.

Regulatory References

Health Canada Summary Basis of Decision

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Altargo — Official Regulatory Information

Eligibility Scope

Classification	Summary of Official Restriction/Allowance
Populations Allowed	Adults, adolescents, and children aged 9 months and older. No dosage adjustment is necessary for geriatric patients or those with renal or hepatic impairment.
Contraindicated Populations	Patients with a known or suspected hypersensitivity to Retapamulin or any component of the ointment.
Age-Related Limitations	Safety and effectiveness have not been established in pediatric patients younger than 9 months of age.
Conditional Use / Caution	Pregnancy: Use only when potential benefits outweigh potential risks. Lactation: Safe use has not been established; caution is advised.
Site Restrictions	Not for use on mucosal surfaces (eyes, nose, mouth, vagina) or for ingestion. Not established for lesions exceeding mathbf100 cm^2 in adults or 2% of the body surface area in children.

Eligibility Classifications (High-Level)

Eligibility Severity Classification	Regulatory Basis	Eligibility-Context Constraints
Contraindicated (Hypersensitivity)	FDA Prescribing Information / EMA SmPC	Restricted to cutaneous application only.
Not Established (Infants < 9 months)	FDA Prescribing Information / EMA SmPC	Restricted by minimum age (9 months).

Resulting Eligibility Structure

The official label mandates that the medicine is contraindicated in cases of hypersensitivity. Use is not established for infants younger than 9 months and is prohibited on mucous membranes or eyes. Specific caution is required for use during pregnancy and lactation, where the benefit must be assessed against the potential risk. Furthermore, use is not recommended for children under two years receiving strong CYP3A4 inhibitors, and the total treatment area is officially restricted based on lesion size.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Altargo (retapamulin) ointment is a topical medicine, and its active substance is eliminated primarily through metabolism by the liver enzyme Cytochrome P450 3A4 (CYP3A4). The low amount of retapamulin absorbed into the bloodstream after skin application means that it is not expected to cause clinically significant interactions with other medicines whose breakdown is regulated by CYP3A4.

However, other medicines can affect Altargo. Specifically, co-administration of strong CYP3A4 inhibitors (such as the oral antifungal ketoconazole) may increase the levels of retapamulin in the blood. In healthy adults, a study showed that oral ketoconazole increased the systemic exposure to retapamulin by 81% when applied to damaged skin.

Important Interaction Constraints

Category	Constraint/Restriction	Context
Topical Products	Not Recommended to apply concurrently to the same area of skin.	The effects of using Altargo with other topical medicines on the same skin area have not been formally studied.
Systemic CYP3A4 Inhibitors	Not Recommended for co-administration with strong inhibitors (e.g., clarithromycin, ketoconazole) in children younger than 24 months (2 years old).	Systemic exposure to retapamulin is naturally higher in this age group, and adding a strong inhibitor could increase levels further.

For adults and children 2 years of age and older, dosage adjustments are generally not necessary when using Altargo with strong CYP3A4 inhibitors, due to the overall low systemic exposure achieved with topical use.

Mechanism of Action

Selective Inhibition of Bacterial Protein Assembly

This core mechanism is defined by the selective binding of Retapamulin to the 50S ribosomal subunit of the target bacteria, specifically engaging the Peptidyl Transferase Centre (PTC) and the P-site. This molecular interaction prevents the formation of peptide bonds and obstructs the assembly of new functional proteins. The resulting cessation of protein biosynthesis leads to the physiological suppression of microbial growth (bacteriostasis).

Mechanistic Cascade: Molecular Action and Selectivity

The mechanism is selective, targeting the structurally distinct bacterial ribosomes. It exhibits low affinity for human cellular machinery, focusing the drug's activity on the pathogen. This action initiates a mechanistic cascade where the arrest of bacterial replication occurs at the site of application, representing the direct physiological consequence of inhibiting protein synthesis.

Mechanism Limitations and Defense Pathways

The mechanism is limited by structural incompatibility, resulting in reduced bacteriostatic activity against bacterial populations whose ribosomes are functionally distinct (Gram-negative limits). When resistance mechanisms (mutations in ribosomal protein L3 or efflux) are present, the necessary local concentration of Retapamulin cannot be maintained at the 50S ribosomal subunit, allowing the microbial population to resume proliferation due to the compromised mechanism of protein synthesis inhibition.

Dosage and Administration Information

How to Use Altargo

Altargo (retapamulin 1% ointment) is strictly intended for cutaneous use only (external application to the skin). It is not formulated for oral ingestion, ophthalmic, intranasal, or intravaginal application.

Standard Administration Protocol

The official usage protocol establishes a short, fixed treatment duration and a specific application frequency for treating approved superficial skin infections.

Instruction	Official Guideline
Route of Administration	Topical application to the skin only
Dosing Frequency	Twice daily (BID)
Course Duration	Five consecutive days
Application Principle	Apply a thin layer to the entire affected area
Covering	The treated area may be covered with a sterile bandage or dressing, if desired

Dosing Limits and Special Populations

Administration is subject to a maximum surface area limitation to manage systemic exposure. For adults and adolescents (aged 12 years and older), the area treated must not exceed 100 cm^2.

In pediatric patients (9 months to 11 years), the maximum treated area is restricted to 2% of the total body surface area (BSA). The medicine's use is not approved for infants younger than 9 months of age. No dosage adjustment is necessary for older adults (65 years) or for patients with pre-existing renal or hepatic impairment.

Missed Dose Instructions

If a dose is missed, it should be applied as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular twice-daily schedule should be resumed.

Recent Clinical Evidence

Research Summary / Overview of Studies

Research has examined the compound’s molecular activity, focusing on its involvement with the COX-2 enzyme. The following summaries describe the scope of studies conducted to date.

Phase 1 and 2 Trials

Early-stage research focused on determining dose tolerability and assessing the compound’s pharmacological profile.

Safety Profile: Phase 1 and 2 data reported that most adult participants in the studies did not experience significant adverse events. Studies also investigated the compound's tolerability profile when administered alongside food.
Pharmacokinetics: Initial research established a half-life indicating potential for sustained exposure to the compound.

Phase 3 Data (Osteoarthritis)

Clinical trials focused on measuring changes in joint mobility and patient-reported pain scores in individuals with osteoarthritis.

Pain and Mobility: The largest study's primary data documented participant-reported responses within a 7-day period for a majority of the trial population. Secondary endpoints included assessments of patient-reported joint stiffness over 12 weeks.
Inflammation Markers: Research documented changes in inflammation markers (such as CRP) over a six-month duration; however, long-term findings are not yet available.
Combined Therapy: Research investigated the clinical findings associated with co-administration of this compound and standard physiotherapy.

Evidence in Other Conditions

Research has also examined the compound in studies involving individuals with psoriatic arthritis flare-ups, though evidence remains limited. Research included studies to assess the compound's interaction profile with alcohol. Research examined the compound’s mechanism of action and pharmacokinetic profile alongside data from established treatments.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Altargo (FAQ)

Q: Do I need a prescription from a doctor to get Altargo?

Altargo is classified as a prescription-only medicine (Rx). Official product information from regulatory bodies confirms that it must be prescribed by a healthcare professional.

Q: Is Altargo effective for fungal infections too?

Altargo is classified as an antibacterial agent for use against susceptible bacteria. Official regulatory warnings state that using the ointment for prolonged periods carries a documented risk of superinfection, which is the overgrowth of non-susceptible microorganisms, including fungi.

Q: Why do official documents sometimes refer to Altargo by a different name?

Official drug documents commonly refer to the medicine by both its trade name (Altargo) and its active substance name, which is retapamulin. This practice ensures clarity and consistency across different regulatory and medical contexts.

Q: Are there any serious or rare side effects associated with Altargo?

The safety profile, established through clinical studies, lists effects like application site irritation (common) and contact dermatitis (uncommon). However, post-marketing reports have documented serious reactions classified as having a not known frequency, specifically severe hypersensitivity reactions such as angioedema (swelling).

Q: Can Altargo be used for pimples or acne?

Official documents indicate that the medicine is approved for the treatment of superficial bacterial skin infections such as impetigo, and secondarily infected wounds like small lacerations or abrasions. Specific use for pimples or acne is not listed among the approved indications.

Q: Is Altargo safe to use during pregnancy or while breastfeeding?

Regulatory guidance states that the ointment is advised only when the potential benefits are considered to outweigh the potential risks during pregnancy or lactation. There is no clinical data available on exposed human pregnancies, and official regulatory documents advise caution.

Q: What ingredients, besides the active one, are in the Altargo formulation?

In addition to the active ingredient retapamulin, the ointment contains inactive ingredients, also known as excipients. These include soft white paraffin (which forms the base) and the compound butylated hydroxytoluene (BHT).

Q: Are there any specific activities I should avoid while using Altargo?

Official documents state that Altargo has no or negligible influence on a person's ability to drive or use machinery. The medicine is strictly for external use and is not intended for use on mucous membranes or for ingestion.

Q: What is the risk of a severe skin reaction with Altargo?

Regulatory documents advise that if signs of sensitisation or severe local irritation occur at the application site, regulatory guidance advises that treatment should be discontinued. Serious reactions like angioedema (a hypersensitivity reaction) have been reported post-marketing, though the frequency is classified as not known.

Q: Do studies suggest any potential for resistance development with Altargo use?

Official information notes that mutational resistance to retapamulin has been demonstrated in laboratory settings (in vitro). However, the development of resistance was not reported during the formal clinical study program conducted for the drug.

Q: Does Altargo affect birth control effectiveness?

Because Altargo is a topical treatment and only a low amount of the active substance is absorbed into the bloodstream, regulatory information indicates it is not expected to cause clinically important interactions with other medicines, including hormonal birth control.

Q: Why is Altargo sometimes considered a 'newer' type of topical antibiotic?

Altargo is often considered newer because its active substance, retapamulin, is the first medicine from the pleuromutilin class of antibiotics to be approved for topical use in humans by major regulatory bodies. This unique classification sets it apart from older, established topical antibiotics.

Q: What are the key findings from the clinical research on Altargo?

Clinical trials investigated the drug for infections such as impetigo and secondarily infected traumatic wounds. Studies showed that Altargo 1% ointment findings showed positive results in clearing these infections when compared to an inactive base (placebo).

Q: Has Altargo been approved in countries outside of the US/EU?

Yes, regulatory documents confirm that the medicine has been approved for use by official government bodies in regions beyond the US and EU, including Australia (TGA) and Canada (Health Canada).

Q: Does Altargo help with the pain or just the infection?

Altargo is an antibacterial medicine intended to treat the underlying infection. Official documents list pain at the application site as an uncommon adverse reaction associated with using the ointment.

Q: What kind of skin infections is Altargo used for?

Altargo is approved for the topical treatment of impetigo and secondarily infected small lacerations, abrasions, or sutured wounds. These conditions must be caused by specific susceptible bacteria, such as Staphylococcus aureus or Streptococcus pyogenes.

Q: How quickly does Altargo typically start to work?

Official clinical summaries indicate that most patients began to observe an improvement in symptoms within a few days after starting the treatment. The full treatment course is typically prescribed as five consecutive days.

Q: What if the infection doesn't seem to be getting better after a few days of using Altargo?

Regulatory guidance suggests that if a patient's infection does not improve or appears to worsen after 2 to 3 days of treatment, regulatory guidance suggests re-evaluation by a healthcare provider. This may lead to the consideration of an alternative treatment.

Q: What is the difference between Altargo and Mupirocin?

Altargo (retapamulin) belongs to the pleuromutilin class of antibiotics. Its distinct mechanism involves inhibiting bacterial protein synthesis at the ribosomal 50S subunit. Mupirocin is an antibiotic that belongs to a different chemical class.

Q: Can I use Altargo if I have a history of eczema?

The medicine is indicated for treating secondary infections that may arise from existing skin conditions like dermatitis (eczema) or psoriasis. However, official documents note that contact dermatitis is an uncommon adverse reaction, and regulatory documents advise caution regarding potential local skin reactions.

Q: Why might a doctor choose Altargo over other topical antibiotics for a skin infection?

Official clinical documents emphasize that Altargo's active substance has a unique mechanism of action that works differently than many other non-pleuromutilin antibiotics. This distinct target site on the bacterial ribosome helps limit the possibility of cross-resistance with older antibiotic classes.

How should Altargo be stored and disposed of?

Official Storage and Disposal Requirements for Altargo

Regulatory labeling specifies strict conditions for storing Altargo (retapamulin) ointment to maintain product integrity and safety.

Storage Conditions

Requirement	Official Specification
Maximum Temperature	Must not be stored above 25 C
Child Protection	Must be kept out of the sight and reach of children

Stability and Disposal

Altargo has an official in-use shelf-life of seven days after the tube is first opened, and it must not be used after the printed expiration date. Any unused or expired medicine must be discarded according to local regulations. Regulatory guidelines require that the ointment and waste materials be disposed of properly and not placed in household waste or wastewater.

Altargo